Chikungunya Virus Antibody (6A11) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-53111
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Virus
Cited:
Human, Virus
Applications
Validated:
Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot
Cited:
Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 6A11
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Live Chikungunya Virus
Epitope
N218 epitope on E2 protein of Chikungunya Virus
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for Chikungunya Virus Antibody (6A11) - BSA Free
Application
Recommended Usage
Western Blot
1:100 - 1:2000
Application Notes
WB: target band at 47kDa. Positive Control: Infected BHK cells.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Chikungunya Virus
Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).
References
1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008
2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417
3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368
Alternate Names
Chikungunya
Additional Chikungunya Virus Products
Product Documents for Chikungunya Virus Antibody (6A11) - BSA Free
Product Specific Notices for Chikungunya Virus Antibody (6A11) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...